What is the role of SGLT2 inhibitors in the treatment of chronic kidney disease (CKD)?

Updated: Jul 21, 2021
  • Author: Pradeep Arora, MD; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Treatment with SGLT2 inhibitors may improve kidney outcomes, especially in patients with DKD. The CREDENCE trial—a double-blind, randomized study of the addition of canagliflozin to RAS blockade in 4401 patients with type 2 diabetes and CKD—was stopped early when an interim analysis showed a significantly lower risk of kidney failure and cardiovascular events in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years. The relative risk of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was 34% lower (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P< 0.001). [57]  The SGLT2 inhibitor dapagliflozin may help prevent and reduce progression of kidney disease in patients with type 2 diabetes, and has been shown to reduce progression of CKD in patients with or without diabetes. [58, 59, 60]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!